Cell and Gene Therapy Catapult and the MHRA collaborate on adeno-associated virus reference material pilot study to support development of gene therapies
The adeno-associated virus serotype 2 (AAV2) standard material was produced at the Cell and Gene Therapy Catapult’s (CGT Catapult) Braintree Manufacturing Innovation Centre, in collaboration with the Medicines and Healthcare products Regulatory Agency (MHRA). The AAV2 was sent to multiple laboratories in the UK, to evaluate how analytical methods used to assess AAV2 varies between laboratories.
Published on the 24th of May 2023. Read the entire news report here, Cell and Gene Therapy Catapult and the MHRA collaborate on adeno-associated virus reference material pilot study to support development of gene therapies.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (20 février 2024). Cell and Gene Therapy Catapult and the MHRA collaborate on adeno-associated virus reference material pilot study to support development of gene therapies. ELSIBI. Consulté le 16 janvier 2025 à l’adresse https://doi.org/10.58079/vvd0
